FDA Prescription Drug Abuse Summary Reports

The FDA Prescription Drug Abuse Summary Reports Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle is focused on providing comprehensive surveillance and research data related to prescription and over-the-counter drug abuse to the U.S. Food and Drug Administration (FDA), specifically the Center for Drug Evaluation and Research's Office of Surveillance and Epidemiology. The contract enables the FDA to obtain specialized reports and datasets that help inform pharmaceutical regulatory efforts, oversight programs, and abuse prevention strategies. These reports are derived from diverse data sources, including treatment centers, individual patient assessments, and comprehensive drug abuse pattern analyses.

Task orders under this IDIQ consistently target post-marketing prescription drug abuse surveillance, with most being firm-fixed price contracts ranging from approximately $30,000 to $1.5 million. Key contractors include Denver Health and Hospital Authority and Inflexxion, Inc., who have received multiple awards to conduct specific research projects such as improving treatment center program data quality, analyzing abuse patterns for specific drugs like hydrocodone and fentanyl, and developing multimedia addiction severity index networks. The task orders are uniformly awarded by the Department of Health and Human Services' FDA, carry no specific set-aside designations, and typically have performance periods between one to five years. Work is predominantly performed in locations like Newton, Massachusetts, and Denver, Colorado, with a strong focus on collecting and analyzing substance abuse treatment and drug diversion data to support regulatory decision-making.